Astellas Sued Over Efforts To Block Generic Prograf

Law360, New York (March 01, 2011, 11:44 PM ET) -- The owners of a retail drug chain filed an antitrust class action Tuesday accusing Astellas Pharma US Inc. of abusing the U.S. Food and Drug Administration’s drug approval process to delay a generic version of Prograf and corner the market for the immunosuppressant.

Stephen L. LaFrance Holdings Inc. filed a complaint in the U.S. District Court for the District of Massachusetts claiming Astellas violated the Sherman Act by illegally maintaining a monopoly in the market for Prograf and charging supracompetitive prices for the drug.

The Pine...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required